Herden, Jan ORCID: 0000-0002-1667-5200, Heidenreich, Axel, Wittekind, Christian and Weissbach, Lothar (2018). Predictive value of the UICC and AJCC 8th edition tumor-nodes-metastasis (TNM) classification for patients treated with radical prostatectomy. Cancer Epidemiol., 56. S. 126 - 133. OXFORD: ELSEVIER SCI LTD. ISSN 1877-783X
Full text not available from this repository.Abstract
Background: According to the 8th-edition of the tumor-nodes-metastasis-classification localized prostate cancer (PCa) can be divided into two categories (cT1, cT2), two stages (SI, SII), and, by incorporating prostate-specific-antigen (PSA) and WHO-grade (Gleason-Score), into prognostic stage groups (PSG I, IIA, IIB, IIC, III). We examined the predictive value of these systems for an organ-confined disease (pT <= 2), favorable WHO-grade <= 2 (Gleason-score <= 7a), and biochemical-free-survival (BFS) after radical prostatectomy (RP). Methods: Data were collected in a prospective, non-interventional, multicenter health-service-research study for the treatment of localized PCa (HAROW) with 687 patients receiving RP. Mean Follow-up was 31.7 months. Results: Organ-confined disease was present in 76.5% and 63.6% of cT1 and cT2 patients, 75.7% and 59.6% of SI and SII, and 84.6%, 81.6%, 72.8% and 42.5% of PSG I, IIA, IIB and >= IIC (p = 0.001). Favorable WHO-grade (Gleason-Score) was present in 75.4% and 60.7% of cT1 and cT2 patients, 74.3% and 56.5% of SI and SII patients, and 86.1%, 85.6%, 73.3% and 29.5% of PSG I, IIA, IIB and >= IIC (p = 0.001). Probability of BFS was 92.0% and 91.5% for cT1 and cT2 (p = 0.990), 91.1% and 94.2% for SI and S II (p = 0.286) and 96.6%, 95.1%, 91.4% and 78.8% for PSG I,IIA,IIB and >= IIC (p = 0.001). Conclusions: CT 1/cT2 and S I/II subgrouping is feasible to predict a different pT-category and a favorable WHO-grade (Gleason-Score) after RP, but failed to predict a different BFS. With the additional information of WHO-grade (Gleason-Score) and PSA, the PSG represents an approach for the prediction of all examined endpoints which is a useful tool to help clinicians to advise their patients.
Item Type: | Journal Article | ||||||||||||||||||||
Creators: |
|
||||||||||||||||||||
URN: | urn:nbn:de:hbz:38-171834 | ||||||||||||||||||||
DOI: | 10.1016/j.canep.2018.08.007 | ||||||||||||||||||||
Journal or Publication Title: | Cancer Epidemiol. | ||||||||||||||||||||
Volume: | 56 | ||||||||||||||||||||
Page Range: | S. 126 - 133 | ||||||||||||||||||||
Date: | 2018 | ||||||||||||||||||||
Publisher: | ELSEVIER SCI LTD | ||||||||||||||||||||
Place of Publication: | OXFORD | ||||||||||||||||||||
ISSN: | 1877-783X | ||||||||||||||||||||
Language: | English | ||||||||||||||||||||
Faculty: | Unspecified | ||||||||||||||||||||
Divisions: | Unspecified | ||||||||||||||||||||
Subjects: | no entry | ||||||||||||||||||||
Uncontrolled Keywords: |
|
||||||||||||||||||||
Refereed: | Yes | ||||||||||||||||||||
URI: | http://kups.ub.uni-koeln.de/id/eprint/17183 |
Downloads
Downloads per month over past year
Altmetric
Export
Actions (login required)
View Item |